A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Celgene

Protocol Number
CC-4047-MM-007

To Learn More Call
201-510-0910